舒肝解郁胶囊联合美沙拉秦治疗溃疡性结肠炎的临床效果

摘要
图/表
参考文献(27)
相关文章 (15)

全文: PDF (672 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨舒肝解郁胶囊联合美沙拉秦治疗溃疡性结肠炎的临床效果。方法回顾性分析2015年6月～2017年1月甘孜藏族自治州人民医院收治的溃疡性结肠炎150例患者的临床资料，按照给药方法的不同将患者分为观察组和对照组，每组各75例。对照组给予常规口服美沙拉秦治疗，观察组在对照组基础上给予舒肝解郁胶囊，均治疗3个月。采用焦虑自评量表（SAS）和抑郁自评量表（SDS）比较治疗前后两组患者的焦虑抑郁水平，采用改良的Mayo评分系统评估疾病的活动程度及治疗效果，采用生存质量问卷（IBDQ）评价治疗后两组患者的生存质量改善情况。比较两组患者治疗前后血中炎症性指标的变化，记录两组患者的不良反应。结果治疗后观察组总有效率明显高于对照组，差异有统计学意义（P ＜ 0.05）。治疗后观察组SAS、SDS评分均明显低于治疗前和对照组，差异均有统计学意义（P ＜ 0.05）；治疗后两组IBDQ评分均高于治疗前，Mayo评分均显著低于治疗前，且观察组IBDQ和Mayo评分改善更加显著，差异均有统计学意义（P ＜ 0.05）。治疗后两组患者血中血小板计数（PLT）、血清中C反应蛋白（CRP）水平均明显低于治疗前，且观察组PLT、CRP水平均显著低于对照组，差异均有统计学意义（P ＜ 0.05）。治疗前后两组患者平均血小板体积水平比较，差异无统计学意义（P ＞ 0.05）。两组患者不良反应发生率比较，差异无统计学意义（P ＞ 0.05）。结论美沙拉秦联合舒肝解郁胶囊能够明显降低溃疡性结肠炎患者炎症水平，改善疾病活动程度，提高治疗效果，进而可显著缓解溃疡性结肠炎患者焦虑、抑郁状态，提高生活质量。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	徐晓红

关键词 ：溃疡性结肠炎, 焦虑, 抑郁, 舒肝解郁胶囊, 炎症

Abstract：Objective To investigate curative effect of Shugan Jieyu Capsules combined with Mesalazin in the treatment of patients with ulcerative colitis. Methods Clinical data of 150 patients with ulcerative colitis admitted to Ganzi Tibetan Autonomous Prefecture People′s Hospital from June 2015 to January 2017 was analyzed retrospectively and divided into the observation group and the control group according to the method of administration, with 75 cases in each group. The control group was treated with oral Mesalazin, while the observation group was treated with Shugan Jieyu Capsules on the basis of the control group. The course of treatment was 3 months in both groups. The self-rating anxiety scale (SAS) and self-rating depression scale (SDS) were applied to compare the levels of anxiety and depression between the two groups before and after treatment. The modified Mayo scoring system was used to evaluate the degree of disease activity and the curative effect. The inflammatory bowel disease questionnaire (IBDQ) was used to evaluate the quality of life after treatment in both groups. The changes of blood inflammatory markers in the both groups were compared before and after treatment, and the adverse reactions were recorded. Results The total effective rate in the observation group was significantly higher than that of control group, with statistically significant difference (P ＜ 0.05). After treatment, the scores of SAS and SDS in the observation group were much lower than those of before treatment and those of control group, with statistically significant differences (P ＜ 0.05); the score of IBDQ was higher than that of before treatment and the score of Mayo was lower than that of before treatment, and the scores in the observation group improved much more remarkably, with statistically significant differences(P ＜ 0.05). After treatment, the levels of platelet count and C-reactive protein were significantly lower than those of before treatment, and the indicators above in the observation group were much more lower than those of control group, with statistically significant differences (P ＜ 0.05). There was no statistically significant difference in the level of platelet volume before and after treatment in the two groups (P ＞ 0.05). There was no statistically significant difference in incidence of adverse reactions between the groups (P ＞ 0.05). Conclusion Mesalazin combined with Shugan Jieyu Capsules can significantly reduce the level of inflammation in ulcerative colitis patients, thereby helping to relieve the extent of disease activity, improve the curative effect. It can effectively alleviate the anxiety and depression, improve the life quality of ulcerative colitis patients.

Key words： Ulcerative colitis Anxiety Depression Shugan Jieyu Capsules Inflammation

引用本文:

徐晓红. 舒肝解郁胶囊联合美沙拉秦治疗溃疡性结肠炎的临床效果[J]. 中国医药导报, 2018, 15(16): 134-137,141.
XU Xiaohong. Clinical effect of Shugan Jieyu Capsules combined with Mesalazin in the treatment of patients with ulcerative colitis. 中国医药导报, 2018, 15(16): 134-137,141.

链接本文:

http://www.yiyaodaobao.com.cn/CN/ 或 http://www.yiyaodaobao.com.cn/CN/Y2018/V15/I16/134

[1] Park KT，Heida A，van Rheenen PF. Standardizing Fecal Calprotectin Monitoring in Asymptomatic Patients with Inflammatory Bowel Disease [J]. Inflamm Bowel Dis，2017， 23（9）：E47.
[2] 陈伟，曹春宇，黎运呈.美沙拉嗪联合双歧杆菌三联活菌治疗溃疡性结肠炎患者的疗效分析[J].中国生化药物，2017，37（3）：90-94.
[3] Tribbick D，Salzberg M，Connell W，et al. Differences Across Illness Perceptions in Inflammatory Bowel Disease and Their Relationships to Psychological Distress and Quality of Life [J]. Gastroenterol Nurs，2017，40（4）：291-299.
[4] Mawdsley JE，Rampton DS. Psychological stress in IBD：new insights into pathogenic and therapeutic implications [J]. Gut，2005，54（10）：1481-1491.
[5] 袁谖.氟哌噻吨美利曲辛片联合治疗溃疡性结肠炎的疗效分析[J].心理医生，2016，22（16）：23-24.
[6] 张发钦，林燕.舒肝解郁胶囊联合美沙拉秦治疗伴焦虑抑郁状态溃疡性结肠炎效果观察[J].现代中西医结合杂志，2017，26（4）：372-374，414.
[7] 中华医学会消化病学会炎症性肠病学组.炎症性肠病诊断与治疗的共识意见（2012年，广州）[J].中华内科杂志，2012，51（10）：818-831.
[8] D'Haens G，Sandborn WJ，Feagan BG，et al. A review of activity indices and efficacy and points for clinical trials of medical therapy in adults with ulcerative colitis [J]. Gastroenterology，2007，132（2）：763-786.
[9] 沈江立，李娜，李惠利.盐酸帕罗西汀辅助治疗老年溃疡性结肠炎伴焦虑、抑郁的疗效分析[J].临床医学研究与实践，2016，1（24）：60-61.
[10] 中华医学会精神病学分会焦虑障碍协作组.综合医院焦虑抑郁诊断和治疗的专家共识[J].中华医学杂志，2012， 92（31）：2174-2181.
[11] Guyatt G1，Mitchell A，Irvine EJ，et al. A new measure of health status for clinical trials in inflammatory bowel disease [J]. Gastroenterology，1989，96（3）：804-810.
[12] 陈峰松，索红军，范辉.疏肝解郁汤治疗腹泻型肠易激综合征例30例[J].世界华人消化杂志，2010，18（25）：2715-2718.
[13] 李楠，卢艳如.盐酸帕罗西汀辅助治疗老年溃疡性结肠炎伴焦虑抑郁40例[J].医药导报，2015，34（7）：903-906.
[14] 赵炳超，张涛.舒肝解郁胶囊联合柳氮磺胺吡啶治疗复发型溃疡性结肠炎的疗效观察[J].现代药物与临床，2015，30（12）1487-1489.
[15] 陈红，徐爱华.中西医结合治疗慢性非特异性溃疡性结肠炎35例疗效观察[J].河北中医，2012，34（12）：1832.
[16] 吴建明，柯潇，张志荣，等.舒肝解郁胶囊在大鼠血清及脑脊液中的成分分析[J].华西药学杂志，2014，29（5）：559-561.
[17] 李勇，谢宜奎，丁红玲，等.美沙拉嗪与康复新液联合治疗溃疡性结肠炎的临床疗效及患者血清细胞因子的变化[J].山东医药，2012，52（25）：55-56.
[18] 罗丹，仝战旗.中医药治疗溃疡性结肠炎的临床研究进展[J].医学综述，2017，23（2）：336-339，343.
[19] 袁浩壬.奥曲肽治疗溃疡性结肠炎的疗效及对细胞因子的影响[J].医学综述，2017，23（9）：1855-1858.
[20] 王革丽.保留灌肠配合针灸治疗溃疡性结肠炎的疗效及对细胞因子的影响[J].医学综述，2016，22（21）：4302-4305.
[21] 张艳.美沙拉嗪联合双歧杆菌三联活菌治疗溃疡性结肠炎的疗效分析[J].中国现代医生，2017，55（31）：43-45.
[22] 王澍琴，王学玲，王岚，等.益生菌联合美沙拉嗪对轻中度溃疡性结肠炎的疗效及对血小板计数、血小板平均体积的影响[J].中国现代医生，2017，55（15）：37-39.
[23] 王澍琴，王学玲，王岚，等.地衣芽孢杆菌联合美沙拉嗪治疗溃疡性结肠炎的疗效及其对血清IL-17、IL-23、TNF-α的影响[J].中国现代医生，2017，55（23）：13-16.
[24] 周继旺，吴建业，陈军贤.序贯应用中药辅助治疗激素依赖性溃疡性结肠炎的临床分析[J].中国现代医生，2016，54（31）：122-125.
[25] Glover M，Smerdon GR，Andreyev HJ，et al. Hyperbaric oxygen for patients with chronic bowel dysfunction after pelvic radiotherapy（HOT2）：a randomised，double-blind，sham-controlled phase 3 trial [J]. Lancet Oncol，2016， 17（2）：224-233.
[26] 赵曼，高峰.溃疡性结肠炎发病机制研究进展[J].现代生物医学进展，2010，10（16）：3160-3165.
[27] Tighe D，Hall B，Jeyarajah SK，et al. One-Year Clinical Outcomes in an IBD Cohort Who Have Previously Had Anti-TNFa Trough and Antibody Levels Assessed [J]. Inflamm Bowel Dis，2017，23（7）：1154-1159.